KNEClinical Trials•globenewswire•
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
Sentiment:Neutral (55)
Summary
(KNE) WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, exceeding its 25-participant target.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 10, 2025 by globenewswire